Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F

Interleukin (IL)-17A is a key driver of inflammation and the principal target of anti-IL-17 therapeutic monoclonal antibodies. IL-17A, and its structurally similar family member IL-17F, have been shown to be functionally dysregulated in certain human immune-mediated inflammatory diseases such as pso...

Full description

Bibliographic Details
Published in:Frontiers in Immunology
Main Authors: Ralph Adams, Asher Maroof, Terry Baker, Alastair D. G. Lawson, Ruth Oliver, Ross Paveley, Steve Rapecki, Stevan Shaw, Pavan Vajjah, Shauna West, Meryn Griffiths
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Subjects:
anti-IL-17A
IL-17A
IL-17F
monoclonal antibody
bimekizumab
dual neutralization
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01894/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.01894/full

Similar Items